Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Merck Kgaa ADR (OP: MKKGY ) 38.22 -0.82 (-2.10%) Streaming Delayed Price Updated: 3:59 PM EDT, Sep 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 15,495 Open 38.77 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 39.04 Today's Range 38.22 - 38.77 52wk Range 28.59 - 39.17 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisition December 12, 2023 Pfizer Inc (NYSE: PFE) Via Benzinga Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis December 06, 2023 Merck KGaA (OTC: MKGAF) (OTC: Via Benzinga Performance YTD +22.85% +22.85% 1 Month +7.63% +7.63% 3 Month +4.74% +4.74% 6 Month +11.40% +11.40% 1 Year +5.00% +5.00% More News Read More Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors September 26, 2023 Via Benzinga Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023 August 03, 2023 Via Benzinga Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List July 26, 2023 Via Benzinga Germany's Merck To Launch Semiconductor Base In China May 31, 2022 Via Benzinga Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation June 20, 2023 Via Benzinga Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions April 18, 2023 Via Benzinga FDA Issues Partial Clinical Hold On Merck Germany's Multiple Sclerosis Study April 12, 2023 Via Benzinga Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer March 27, 2023 Via Benzinga Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval March 23, 2023 Via Benzinga With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics January 20, 2023 Via Benzinga PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment January 03, 2023 Via Benzinga Mersana Inks Cancer Therapy Development Deal With Merck Germany December 23, 2022 Via Benzinga SpaceX Starlink's New In-Flight Connectivity Service, Amazon's NY Workers Reject Union, Celsius Network Faces Several Federal Investigations: Top Stories Wednesday, Oct. 19 October 19, 2022 Via Benzinga Germany's Merck Slapped With Formal French Investigation Related To Its Thyroid Drug October 19, 2022 Via Benzinga PDS Biotech Highlights Expanded Data From PDS0101 Triple Combination Trial In HPV-Positive Cancers October 11, 2022 Via Benzinga TSM Looks To Hire Over 8,000 People In 2022 January 24, 2022 Via Benzinga Despite Palantir’s Impressive Deals, Its Losses and Valuation Make It Unappetizing January 21, 2022 Via InvestorPlace The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings November 18, 2021 Via Benzinga GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact September 30, 2021 Via Benzinga Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study September 21, 2021 Via Benzinga Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial August 24, 2021 Via Benzinga Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck June 01, 2021 Via Benzinga Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors June 01, 2021 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
